Why Two Receptors Beat One
GLP-1 acts mainly on satiety and insulin secretion. GIP adds direct adipose-tissue effects and appears to modulate the nausea pathway centrally, which is why tolerability holds even as efficacy climbs.
Weight Management · Dual Agonist
Tirzepatide
Dual incretin action for the deepest documented weight reduction.
Tirzepatide activates both GIP and GLP-1 receptors. The dual mechanism produces greater appetite suppression and better insulin sensitivity than GLP-1 alone, with the largest average weight reduction of any approved non-surgical therapy.
20.9%
Mean body weight reduction
72 weeks, SURMOUNT-1, 15 mg
57%
Achieved ≥20% weight loss
highest dose arm
2
Receptors targeted
GIP + GLP-1
Clinical Benefits
What Tirzepatide Does in the Body
Greater Average Loss than GLP-1 Alone
Head-to-head data (SURMOUNT-5) showed roughly 20.2% loss with tirzepatide vs 13.7% with semaglutide at 72 weeks.
Improved Insulin Sensitivity
GIP activity enhances adipose tissue glucose uptake and lipid handling, complementing GLP-1's pancreatic effect.
Better Tolerability at Equivalent Effect
Many patients report that GIP co-agonism moderates the nausea burden relative to the weight loss achieved.
Sleep Apnea and Comorbidity Benefit
Trials demonstrated significant reductions in apnea-hypopnea index and blood pressure alongside weight change.
Wide Titration Ladder
Six dose levels from 2.5 mg to 15 mg let your physician find the lowest effective dose instead of defaulting to maximum.
Once-Weekly Simplicity
A single injection on a fixed day each week — no daily pills, no timing around meals.
Mechanism of Action
How It Actually Works
Glucose-dependent insulinotropic polypeptide (GIP) is the second major incretin hormone. Tirzepatide is a single 39-amino-acid peptide engineered to bind both GIP and GLP-1 receptors, with fatty-acid modification for weekly dosing.
- 01
Dual Receptor Engagement
One molecule activates two complementary incretin pathways simultaneously.
- 02
Adipose Signaling
GIP receptor activity in fat tissue improves lipid buffering and insulin sensitivity.
- 03
Central Satiety
GLP-1 signaling in the hypothalamus reduces hunger drive and food reward.
- 04
Gastric Slowing
Delayed emptying extends fullness and blunts post-meal glucose excursions.
Education
What Your Physician Wants You to Understand
Dose Is a Tool, Not a Target
Many patients plateau comfortably at 7.5 or 10 mg. We escalate only when the rate of loss stalls and side effects are controlled — the goal is the lowest dose that maintains progress.
Body Composition Matters
We track waist, weight, and where available DEXA or bioimpedance — not the scale alone. Protein targets and resistance training are part of the prescription.
Sourcing and Quality
Compounded through U.S. PCAB-accredited pharmacies with API from FDA-registered facilities. Certificates of analysis available on request.
Peer-Reviewed Evidence
The Trials Behind the Protocol
SURMOUNT-1 (NEJM, 2022)
2,539 adults without diabetes; −20.9% mean weight change at 15 mg over 72 weeks.
New England Journal of Medicine
SURMOUNT-5 (NEJM, 2025)
Head-to-head vs semaglutide 2.4 mg: −20.2% vs −13.7% at 72 weeks.
New England Journal of Medicine
SURMOUNT-OSA (NEJM, 2024)
Significant reduction in apnea-hypopnea index in patients with obesity and moderate-to-severe OSA.
New England Journal of Medicine
Titration Schedule
A Typical Dosing Ladder
Illustrative only. Your physician sets and adjusts your schedule based on tolerance, labs and rate of progress — escalation is never automatic.
| Phase | Dose | Clinical note |
|---|---|---|
| Weeks 1–4 | 2.5 mg weekly | Initiation dose, not therapeutic. |
| Weeks 5–8 | 5 mg weekly | First maintenance-capable dose. |
| Weeks 9–12 | 7.5 mg weekly | Escalate only if tolerated. |
| Weeks 13–16 | 10 mg weekly | Many patients hold here long term. |
| Week 17+ | 12.5–15 mg weekly | Reserved for stalled progress. |
Candidacy
Is This Right for You?
Often a Good Fit
- BMI ≥ 30, or ≥ 27 with a weight-related condition
- Insulin resistance or type 2 diabetes
- Inadequate response to a GLP-1 alone
- Obstructive sleep apnea or hypertension with obesity
Not Appropriate If
- Medullary thyroid carcinoma or MEN2 history
- Prior pancreatitis
- Active eating disorder
- Pregnancy or breastfeeding
Safety Profile
Side Effects, Stated Plainly
Most side effects are dose-dependent and resolve with slower titration. Your care team is reachable by message, and holding a dose is always an option.
Common
- Nausea, typically dose-escalation related
- Constipation or diarrhea
- Decreased appetite and early fullness
- Fatigue in the first weeks
- Injection-site reactions
Serious — Contact Us Immediately
- Pancreatitis — seek care for severe persistent abdominal pain
- Gallbladder disease with rapid loss
- Contraindicated with medullary thyroid carcinoma or MEN2 history
- Not for use in pregnancy or while breastfeeding
Comparison
How It Compares
| Therapy | Mechanism | Avg. weight change | Frequency |
|---|---|---|---|
| Tirzepatide | GIP + GLP-1 agonist | ~21% | Weekly |
| Semaglutide | GLP-1 agonist | ~15% | Weekly |
| Liraglutide | GLP-1 agonist | ~8% | Daily |
FAQ
Tirzepatide Questions
Is tirzepatide just a stronger semaglutide?+
No — it is a different molecule with an added mechanism. The GIP component changes adipose signaling, not just the intensity of GLP-1 effect.
Can I switch from semaglutide?+
Yes. Most patients transition at 2.5 or 5 mg tirzepatide one week after their last semaglutide dose, guided by your physician.
Do I need to reach 15 mg?+
Most patients do not. The correct dose is the lowest one producing steady progress with manageable side effects.
How Is It Shipped?+
Overnight to any California address, in discreet temperature-controlled packaging, with syringes, alcohol prep pads, and a sharps disposal plan included. We ship within California only.
Also in the formulary
MW-102
Semaglutide
The clinical gold standard for appetite regulation.
View protocolMW-501
BPC-157
A gastric peptide studied for systemic tissue repair.
View protocolMW-502
TB-500
A synthetic fragment of Thymosin Beta-4 studied for soft-tissue recovery.
View protocolMW-503
CJC-1295 / Ipamorelin
A paired secretagogue protocol that supports your own growth hormone rhythm.
View protocolMW-701
NAD+ Injectable
A mitochondrial cofactor protocol for energy, focus and cellular repair.
View protocolMW-103
Semaglutide (Oral)
The same GLP-1 signal, taken as a daily oral dose instead of a weekly injection.
View protocolMW-702
MOTS-c
A mitochondrial-derived peptide studied for metabolic flexibility and exercise-like signaling.
View protocolMW-601
PT-141 (Bremelanotide)
An on-demand therapy that works on desire in the brain, not blood flow in the body.
View protocolMW-602
Semax / Selank
Intranasal peptides studied for focus, stress resilience and neurotrophic support.
View protocolMW-504
Sermorelin
The original growth hormone-releasing peptide — simpler and gentler than newer secretagogue combinations.
View protocolSee If Tirzepatide Is Right for You
A two-minute intake, reviewed by a licensed physician. No obligation, no membership fee.